Arrowhead Stock Today

ARWR
 Stock
  

USD 31.20  1.57  5.30%   

Market Performance
0 of 100
Odds Of Distress
Less than 1
Arrowhead Pharma is selling at 31.20 as of the 27th of September 2022; that is 5.30 percent increase since the beginning of the trading day. The stock's lowest day price was 30.04. Arrowhead Pharma has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Arrowhead Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of August 2022 and ending today, the 27th of September 2022. Click here to learn more.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Arrowhead Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 105.85 M outstanding shares of which 4.18 M shares are presently shorted by private and institutional investors with about 5.71 trading days to cover. More on Arrowhead Pharma

Moving together with Arrowhead Pharma

+0.62HPQHp Inc Fiscal Year End 22nd of November 2022 PairCorr

Arrowhead Pharma Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Arrowhead Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Arrowhead Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Arrowhead Pharma generated a negative expected return over the last 90 days
Arrowhead Pharma has high historical volatility and very poor performance
Arrowhead Pharma is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 249.94 M. Net Loss for the year was (153.93 M) with profit before overhead, payroll, taxes, and interest of 138.29 M.
Arrowhead Pharma currently holds about 416.5 M in cash with (91.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.93.
Roughly 70.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.nasdaq.com: Swelling losses havent held back gains for Arrowhead Pharmaceuticals shareholders since theyre up 646 percent over 5 years - Nasdaq
CEOChristopher Anzalone
Average Analyst Recommendation
Analysts covering Arrowhead Pharma report their recommendations after researching Arrowhead Pharma's financial statements, talking to executives and customers, or listening in on Arrowhead Pharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Arrowhead Pharma. The Arrowhead consensus assessment is calculated by taking the average forecast from all of the analysts covering Arrowhead Pharma.
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Arrowhead Pharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Arrowhead Pharma (ARWR) is traded on NASDAQ Exchange in USA and employs 329 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 3.33 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arrowhead Pharma's market, we take the total number of its shares issued and multiply it by Arrowhead Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Arrowhead Pharma conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 105.85 M outstanding shares of which 4.18 M shares are presently shorted by private and institutional investors with about 5.71 trading days to cover. Arrowhead Pharma currently holds about 416.5 M in cash with (91.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.93.
Check Arrowhead Pharma Probability Of Bankruptcy
Ownership
Arrowhead Pharma retains a total of 105.85 Million outstanding shares. Over half of Arrowhead Pharma outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Arrowhead Pharma. Please watch out for any change in the institutional holdings of Arrowhead Pharma as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Arrowhead Ownership Details

Arrowhead Stock Price Odds Analysis

In regard to a normal probability distribution, the odds of Arrowhead Pharma jumping above the current price in 90 days from now is about 98.0%. The Arrowhead Pharma probability density function shows the probability of Arrowhead Pharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.7593. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Arrowhead Pharma will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Arrowhead Pharma is significantly underperforming DOW.
  Odds Below 31.2HorizonTargetOdds Above 31.2
2.40%90 days
 31.20 
97.58%
Based on a normal probability distribution, the odds of Arrowhead Pharma to move above the current price in 90 days from now is about 98.0 (This Arrowhead Pharma probability density function shows the probability of Arrowhead Stock to fall within a particular range of prices over 90 days) .

Arrowhead Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Arrowhead Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arrowhead Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arrowhead Pharma's value.
InstituionSecurity TypeTotal SharesValue
Blackrock IncCommon Shares12.3 M432.5 M
Vanguard Group IncCommon Shares10.1 M354.5 M
View Arrowhead Pharma Diagnostics

Arrowhead Pharma Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Arrowhead Pharma market risk premium is the additional return an investor will receive from holding Arrowhead Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Arrowhead Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Arrowhead Pharma's alpha and beta are two of the key measurements used to evaluate Arrowhead Pharma's performance over the market, the standard measures of volatility play an important role as well.

Arrowhead Stock Against Markets

Picking the right benchmark for Arrowhead Pharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Arrowhead Pharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Arrowhead Pharma is critical whether you are bullish or bearish towards Arrowhead Pharma at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Arrowhead Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stock Screener Now

   

Stock Screener

Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
All  Next Launch Module

Arrowhead Pharma Corporate Directors

Arrowhead Pharma corporate directors refer to members of an Arrowhead Pharma board of directors. The board of directors generally takes responsibility for the Arrowhead Pharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Arrowhead Pharma's board members must vote for the resolution. The Arrowhead Pharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Charles McKenney - Independent DirectorProfile
Michael Perry - Independent DirectorProfile
Douglass Given - DirectorProfile
Mauro Ferrari - Scientific Advisor, Director, Member of Nomination Committee and Member of Compensation CommitteeProfile

Invested in Arrowhead Pharma?

The danger of trading Arrowhead Pharma is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arrowhead Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arrowhead Pharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arrowhead Pharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for analysis

When running Arrowhead Pharma price analysis, check to measure Arrowhead Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharma is operating at the current time. Most of Arrowhead Pharma's value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arrowhead Pharma's price. Additionally, you may evaluate how the addition of Arrowhead Pharma to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Is Arrowhead Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharma. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Arrowhead Pharma is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharma's value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharma's market value can be influenced by many factors that don't directly affect Arrowhead Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arrowhead Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arrowhead Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.